Melatonin delays ovarian aging in mice by slowing down the exhaustion of ovarian reserve

Chan Yang; Qinghua Liu; Yingjun Chen; Xiaodong Wang; Zaohong Ran; Fang Fang; Jiajun Xiong; Guoshi Liu; Xiang Li; Liguo Yang; Changjiu He

doi:10.1038/s42003-021-02042-z

. 2021 May 6;4:534. doi: 10.1038/s42003-021-02042-z

Melatonin delays ovarian aging in mice by slowing down the exhaustion of ovarian reserve

Chan Yang ^1,^2,^3,^#, Qinghua Liu ^1,^2,^3,^#, Yingjun Chen ^1,^2,³, Xiaodong Wang ^1,^2,³, Zaohong Ran ^1,^2,³, Fang Fang ^1,^2,³, Jiajun Xiong ^1,^2,³, Guoshi Liu ⁴, Xiang Li ^1,^2,³, Liguo Yang ^1,^2,³, Changjiu He ^1,^2,^3,^✉

PMCID: PMC8102596 PMID: 33958705

Abstract

Studies have shown that melatonin (MLT) can delay ovarian aging, but the mechanism has not been fully elucidated. Here we show that granulosa cells isolated from mice follicles can synthesize MLT; the addition of MLT in ovary culture system inhibited follicle activation and growth; In vivo experiments indicated that injections of MLT to mice during the follicle activation phase can reduce the number of activated follicles by inhibiting the PI3K-AKT-FOXO3 pathway; during the early follicle growth phase, MLT administration suppressed follicle growth and atresia, and multiple pathways involved in folliculogenesis, including PI3K-AKT, were suppressed; MLT deficiency in mice increased follicle activation and atresia, and eventually accelerated age-related fertility decline; finally, we demonstrated that prolonged high-dose MLT intake had no obvious adverse effect. This study presents more insight into the roles of MLT in reproductive regulation that endogenous MLT delays ovarian aging by inhibiting follicle activation, growth and atresia.

Subject terms: Animal breeding, Endocrine reproductive disorders

Chan Yang, Qinghua Liu, et al. use in vitro and SNAT-null mouse models to investigate the role of melatonin in ovarian aging. Their results suggest that melatonin can delay ovarian aging by inhibiting follicle activation, growth and atresia, providing more insight into how melatonin impacts reproduction.

Introduction

The exhaustion of ovarian follicle reserve leads to the loss of ovarian function in middle-aged females, namely ovarian aging¹. It is generally accepted that ovarian aging result in the loss of reproductive capability and the disorder of reproductive hormones; the latter further trigger many diseases including cardiovascular disease, ovarian cancer, osteoporosis, obesity, and menopausal syndrome^2–5. Therefore, the impact of ovarian aging reaches far beyond just the reproductive system and it also indirectly causes dysfunction of other organs⁶. With the development of medical technology, the various risks posed by elderly pregnancy can be technically avoided. Therefore, the treatment or delay of ovarian aging is becoming an urgent need for women.

The mainstream view tends to suggest that there are no germline stem cells in the ovary to continuously replenish the ovarian follicle reserve. Therefore, the exhaustion of the ovarian follicle reserve in middle-aged females is the direct cause of ovarian aging^7,8. Early folliculogenesis, which begins with primordial follicle activation and ends with the formation of small antral follicle (SAF), is directly responsible for the decrease of ovarian follicle reserve⁹. The primordial follicle pool established during fetal or neonatal period is believed to be the pre-established ovarian follicle reserve (PreOR), which maintains the entire reproductive lifespan of the females¹⁰. During early folliculogenesis, a limited number of primordial follicles are constantly activated from PreOR. The activation rate of follicles is strictly regulated; if not, it will cause premature ovarian failure¹¹. Subsequently, the activated follicles develop into primary, secondary, and eventually SAFs, a process also known as early follicle growth¹². All the SAFs constitute a dynamic ovarian follicle reserve (DOR), the size of which determines how many follicles are selected for cyclic recruitment by gonadotrophin (GTH), or eliminated via atresia.

PreOR and DOR are functionally related and their dynamics are mainly controlled by two pathways, the PI3K-AKT and the BMP/AMH-SMAD¹³. On one hand, DOR can be continuously replenished by the activated follicles from PreOR to maintain its size. Hereby, the number of SAFs in the DOR remain stable before the reproductive ability declines¹⁴, although the number of primordial follicles in the ovary continues to decrease. On the other hand, as the ovary ages, the number of primordial follicles in PreOR greatly decreases, which indirectly leads to reduction in SAFs in DOR. Therefore, the extent of ovarian aging can be reflected by SAF count^15,16. Of note, SAFs in the DOR will be eliminated via atresia if without sufficient GTH and the number of ovulated eggs per estrous cycle is also fixed. Therefore, the larger the size of DOR, the more SAFs will be eliminated to ensure the stability of fecundity and, accordingly, more primordial follicles will be activated from PreOR to replenish the loss of DOR. Such vicious cycle will eventually result in a meaningless exhaustion of ovarian follicle reserve^13,17,18. Hence, the vast majority of follicles will be eliminated before puberty, because the hypothalamic pituitary is not mature enough to produce sufficient GTH¹⁹. In a word, inhibition of early folliculogenesis can directly slow down the exhaustion of ovarian follicle reserve.

Studies have shown that the level of reactive oxygen species (ROS) and inflammatory factors significantly increase in ovary during the function decline period^20,21. Therefore, researchers have tried some antioxidants to delay ovarian aging such as vitamin C, vitamin E, N-acetyl-l-cysteine, curcumin, coenzyme Q10, proanthocyanidin, quercetin, and resveratrol, and have achieved positive results²². As the most representational antioxidant, melatonin (MLT) is also used to delay ovarian aging^23–30. Studies have demonstrated that shortening the sunshine time can delay reproductive aging, which is considered to be related to MLT^31,32; long-term administration of MLT in the drinking water of mice can reduce the production of ROS in the ovary, thereby increasing the number of follicles in middle-aged mice^27,29. MLT administration for rats during the reproductive decline period can help maintain a regular estrous cycle and normal estrogen level, and extend their reproductive age³³. Clinical study has also found that 6-month MLT administration for perimenopausal and postmenopausal women can decrease the serum GTH level and improve thyroid function³⁴.

However, there are still several important issues to be elucidated with respect to the research topic of MLT delaying ovarian aging. First, studies have demonstrated that long-term intake of exogenous MLT can effectively delay ovarian aging. However, the question is whether endogenous MLT is involved in the regulation of ovarian aging and, if so, to what extent? Second, in light of the free radical theory of aging, it was generally believed that the antioxidant property of MLT is the pivotal reason for delaying aging³⁵. Nevertheless, unlike body aging, the cause of ovarian aging is the exhaustion of the ovarian follicle reserve. Thus, in addition to the antioxidant property, does MLT delay ovarian aging by inhibiting the loss of ovarian follicle reserve? To address these issues, we conducted this study using a mouse model and, finally, demonstrated that endogenous MLT delayed ovarian aging by slowing down the exhaustion of ovarian reserve.

Results

MLT may play a regulatory role in early folliculogenesis

Immunohistochemical data indicated that SNAT, the rate-limiting enzyme in the MLT synthetic pathway, was mainly distributed in the granulosa cells (GCs) (Fig. 1a). Then we examined whether MLT can be synthesized in GCs. To this end, isolated GCs were cultured with or without 5-hydroxytryptamine (5-HT), the precursor of MLT and SNAT substrate (Fig. 1b). High-performance liquid chromatography (HPLC) was used to detect the conversion of 5-HT into MLT. In three cases, namely no addition of GCs and 5-HT (#1–3), the addition of 5-HT but no GCs (#4–6), and the addition of GCs but no 5-HT (#7–9), no MLT was detected in the culture medium. When both GCs and 5-HT were added to the medium (#10–12), MLT absorption peak appeared in the chromatography (Fig. 1c). The above results indicated that follicles have the capacity to synthesize MLT.

Fig. 1 — a Location of SNAT in prepubertal ovaries was determined by immunohistochemistry. NC represents negative control. b, c Detection of the MLT-synthetic ability of GCs. b Experimental design. c Representative chromatograms showing metabolites extracted from culture medium alone (#1–3), culture medium with 5-HT but no GCs (#4–6), culture medium with GCs but no 5-HT (#7–9), and culture medium with GCs and 5-HT (#10–12). Absorption peaks of MLT only appear in GCs incubated with 5-HT (#10–12, retention time 4.44 min). d The expression profiles of *SNAT*, *Fshr*, and *Lhcgr* in prepubertal ovaries were determined by qPCR (values are mean ± SEM). Normalization was performed using the housekeeping gene *Actb*. n = 3 biologically independent samples. e MLT levels in ovary homogenate (values are mean ± SEM). n = 4 (PD7, 9), 5 (PD15), and 6 (PD17, 19) biologically independent samples, respectively. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. Significant differences are denoted by *P < 0.05 and **P < 0.01.

Subsequently, we collected ovaries at postnatal day (PD) 5, 7, 9, 11, 13, 15, 17, 19, and 21. The quantitative reverse-transcription PCR (qRT-PCR) data showed that the expression level of SNAT in the ovary continued to decrease; Fshr and Lhcgr are the marker genes that reflected the process of folliculogenesis, and their expression levels gradually increased in the same process, which is opposite to the expression pattern of SNAT (Fig. 1d). Next, we examined the MLT level in ovarian homogenates at PD7, 9, 15, 17, and 19. Similar to the expression pattern of SNAT, the changes in MLT level gradually decreased with age (Fig. 1e). The above data suggested that MLT may be involved in the regulation of early folliculogenesis.

MLT addition inhibited early folliculogenesis in in vitro ovary culture system

To investigate whether MLT is involved in the regulation of primordial follicle activation in in vitro culture system, ovaries from mice at PD3 were cultured in vitro and then the number of activated follicles with and without MLT was counted (Fig. 2a, b). The result showed a significant decrease in the number of activated follicles after both 10⁻⁸ M and 10⁻⁷ M MLT addition (P = 0.0394 and 0.025, respectively). In addition, 10⁻⁸ and 10⁻⁷ M MLT can also significantly reduce the number of atretic follicles (P = 0.0032 and 0.0001, respectively) (Fig. 2c, d).

To further study the effect of MLT on early follicle growth, ovaries from mice at PD10 were isolated and cultured in vitro (Fig. 2e). Then the number of type 5a follicles in the ovaries with and without MLT addition was counted, respectively. It was found that both 10⁻⁸ M and 10⁻⁷ M MLT can significantly reduce the number of type 5a follicles (P = 0.0348 and 0.0418, respectively). Despite the downward trend, the number of atretic follicles did not decrease significantly after MLT addition (Fig. 2f, g).

In vivo MLT intake inhibited follicle activation through PI3K-AKT-FOXO3 pathway

To study the effect of MLT on primordial follicle activation in vivo, the mice were injected with different doses of MLT starting from PD3 to PD9 (Fig. 3a). The result showed that 1 and 15 mg kg⁻¹ doses of MLT significantly reduced the number of activated follicles (P = 0.0032 and 0.0005, respectively). It indicated that exogenous MLT intake can inhibit follicle activation. Despite the downward trend, MLT had no significant impact on follicular atresia (Fig. 3b). For the convenience of research, we used 15 mg kg⁻¹ as the optimal dose of MLT for subsequent experiments.

Fig. 3 — a, b The effect of MLT injection on follicle activation and atresia. n = 3 biologically independent mice. a Experimental design and representative photographs of H&E staining in each group. The scale bars are 100 µm in the original images and 50 µm in the enlarged images. b The statistical charts of activated and atretic follicles (values are mean ± SEM). The number of sections used for statistics: Con n = 11; 0.1 mg kg⁻¹ MLT n = 11; 1 mg kg⁻¹ MLT n = 12; 15 mg kg⁻¹ MLT n = 10. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. c, d The effect of MLT injection on FOXO3 translocation in the oocytes at PD6 and PD9. n = 2 biologically independent mice. c Representative photographs of immunofluorescent staining. The red arrow indicates cytosolic localization, the yellow arrow indicates nuclear localization. The scale bars are 100 µm in the original images and 20 µm in the enlarged images. d The statistical charts of FOXO3 distribution (values are mean ± SEM). The number of sections used for statistics: PD6 n = 6; PD9 n = 8 (Con), 12 (15 mg kg⁻¹ MLT). Statistical significance was determined using two-tailed unpaired Student’s t-test. e The effect of MLT injection on mTOR, PI3K-AKT, and Hippo pathways in ovaries. The relative optical density was normalized by the amount of the loading control β-Actin on the same membrane (values are mean ± SEM). The original western blottings can be viewed in Supplementary Fig. 5. n = 4 biologically independent mice. Statistical significance was determined using two-tailed unpaired Student’s t-test. f The effect of MLT injection on the expression of antioxidant genes in the ovaries (values are mean ± SEM). *GSH-PX*: n = 4 (Con), 5 (15 mg kg⁻¹ MLT); *SOD2*: n = 5 (Con), 4 (15 mg kg⁻¹ MLT); *CAT*: n = 5 (Con), 4 (15 mg kg⁻¹ MLT). Normalization was performed using the housekeeping gene *Actb*. Statistical significance was determined using two-tailed unpaired Student’s t-test. g The effect of MLT injection on the levels of SOD and T-AOC in the ovaries (values are mean ± SEM). n = 6 (SOD), 5 (T-AOC) biologically independent samples, respectively. Statistical significance was determined using two-tailed unpaired Student’s t-test. Significant differences are denoted by *P < 0.05 and **P < 0.01.

The mTORC1 and PI3K-AKT-FOXO3 are the pivotal pathways that control primordial follicle activation. In general, FOXO3 localizes to the oocyte nucleus in the dormant follicle, but exports to the cytoplasm to activate primordial follicle when phosphorylated by PI3K-AKT pathway, which can be activated by mTORC1 pathway^36,37. Immunofluorescent staining experiment demonstrated that MLT intake significantly inhibited nuclear exclusion of FOXO3 (PD6: P = 0.022; PD9: P = 0.0235) (Fig. 3c, d). Moreover, the data of western blotting revealed that MLT intake significantly inhibited the phosphorylation of Akt (P = 0.0314), although it did not affect mammalian target of rapamycin (mTOR) pathway. We further investigated whether MLT inhibits follicle activation through the Hippo pathway, which has been proved to be involved in inhibiting follicle activation and growth^38–40. The data demonstrated that MLT intake did not affect Hippo pathway, as the expression of key genes in Hippo pathway (YAP, LATS1, LATS2, TAZ, MOB1b, and SAV1) (Supplementary Fig. 1) and phosphorylation of Yap did not change (Fig. 3e). We also studied whether the inhibiting effect of MLT on follicle activation is mediated by transmembrane receptors. It was observed that Mtnr1a but not Mtnr1b was expressed in neonatal mouse ovary and the constitutive expression level of Mtnr1a was not high (Supplementary Fig. 2a). Later, we added a competitive inhibitor of Mtnr1a—Luzindole, ten times the concentration of MLT—to the in vitro culture system, which still could not offset the inhibiting effect of MLT on follicle activation (Supplementary Fig. 2b, c).

We also investigated the antioxidant capacity of MLT and observed that short-term MLT intake significantly upregulated the expression of superoxide dismutase-2 (SOD2) in the ovaries (P = 0.042) (Fig. 3f). Similar to the gene expression data, the level of SOD significantly increased after MLT intake (P = 0.0114) (Fig. 3g). In addition, the serum levels of glutathione peroxidase (GSH-PX), SOD, catalase (CAT), and total antioxidant capacity (T-AOC) increased after MLT intake (P = 0.0000). In contrast, molondialdehyde (MDA), the metabolite of lipid peroxidation products significantly decreased after MLT intake (P = 0.0000) (Supplementary Fig. 3). These data all indicated that MLT can effectively improve the antioxidant capacity of the ovary, which is consistent with previous report²⁷.

In vivo MLT intake inhibited early follicle growth and atresia

To study the effect of MLT on early follicle growth and atresia in vivo, we performed continuous MLT injection on mice from PD10 and collected ovaries at PD15, 17, 19, and 21 for histological analysis (Fig. 4a). At PD15, the number of type 5b follicles in MLT intake group was significantly reduced (P = 0.0038); at PD17, the number of type 5b follicles and atretic follicles in MLT intake group was significantly reduced (P = 0.0017 and 0.0000, respectively); the number of SAFs and atretic follicles was significantly reduced at PD19 (P = 0.0064 and 0.0000, respectively) and PD21 (P = 0.0012 and 0.0097, respectively) (Fig. 4b). It was also found that the diameter of oocytes in early growing follicles did not show significant differences after MLT intake (Fig. 4c). During early folliculogenesis, Fshr and Lhcgr are mainly expressed in follicles at the phase of type 5b and SAF; therefore, the expression levels of the two genes can indirectly reflect the number of follicles at the phase of type 5b and SAF in the ovary. The results of qRT-PCR showed that MLT intake reduced the expression levels of Fshr and Lhcgr in the ovaries at PD17 (Fshr: P = 0.0052; Lhcgr: P = 0.09) and PD19 (Fshr: P = 0.0392; Lhcgr: P = 0.0387) (Fig. 4d).

Fig. 4 — a–c The effect of MLT injection on early follicle growth and atresia, and oocyte growth. n = 4 biologically independent mice. a Experimental design and representative photographs of H&E staining in each group. The scale bar = 200 µm. b The statistical charts of the number of early growing follicles and atretic follicles (values are mean ± SEM). c The statistical charts of the number of oocyte diameters (values are mean ± SEM). The number of sections used for statistics: PD15 n = 24; PD17 n = 33 (Con), 35 (MLT); PD19 n = 37 (Con), 34 (MLT); PD21 n = 38 (Con) and 36 (MLT). Statistical significance was determined using two-tailed unpaired Student’s t-test. d The effect of MLT injection on the expression of *Fshr* and *Lhcgr* (values are mean ± SEM). Normalization was performed using the housekeeping gene *Actb*. PD17: n = 4 (Con), 3 (MLT); PD19: n = 4 (Con), 4 (MLT); PD21: n = 4 (Con), 3 (MLT). Statistical significance was determined using two-tailed unpaired Student’s t-test. e, f The effect of MLT injection on the number of ovulated oocytes after superovulation. e Representative photographs of reproductive organs after superovulation. f The statistical chart of the number of ovulated oocytes (values are mean ± SEM). The number of mice used for superovulation: PD15 n = 4 (Con), 3 (MLT); PD17 n = 8; PD19 n = 9; PD21 n = 9. Statistical significance was determined using two-tailed unpaired Student’s t-test. g, h The effect of MLT injection on the number of implanted embryos. g Representative photographs of implanted embryos in each group. h The statistical charts of the number, size, and distribution of implanted embryos. n = 21 (Con), 25 (MLT) biologically independent mice, respectively. Statistical significance was determined using two-tailed unpaired Student’s t-test or χ²-test. i The volcano map of genes. n = 3 biologically independent mice. j GO analysis of differentially expressed genes. k, l The detection of MLT’s effect on PCNA using immunohistochemistry and qPCR, respectively. k Representative photographs of immunohistochemistry. The scale bars are 200 µm in the original images and 50 µm in the enlarged images. l Gene quantification of *PCNA* (values are mean ± SEM). Normalization was performed using the housekeeping gene *Actb*. n = 4 biologically independent mice. Statistical significance was determined using two-tailed unpaired Student’s t-test. m, n KEGG analysis of differentially expressed genes. m KEGG analysis of differentially expressed genes. The typical pathways associated with folliculogenesis are shown in yellow box. n Signaling pathways interaction network. The blue dots represent downregulation and red dots represent upregulation. o The detection of MLT’s effect on PI3K-AKT pathway using western blotting. The relative optical density was normalized by the amount of the loading control Gapdh on the same membrane (values are mean ± SEM). The original western blottings can be viewed in Supplementary Fig. 6. n = 4 biologically independent mice. Statistical significance was determined using two-tailed unpaired Student’s t-test. Significant differences are denoted by *P < 0.05 and **P < 0.01.

The formation of small follicular antrum means that they can respond to GTH stimulation, so the number of ovulated oocytes indirectly reflects the number of SAFs in the ovary. Therefore, to obtain more phenotypic evidences that MLT inhibits early follicle growth, superovulation experiment was conducted. It was observed that, at PD19, the number of ovulated oocytes in MLT intake group was significantly lower than that in control group (P = 0.043) (Fig. 4e, f). In addition, the decrease in the number of SAFs means the decrease in the number of follicles involved in cyclic recruitment, which indirectly leads to the decrease in the number of implanted embryos after mating. Therefore, to further demonstrate the inhibitory effect of MLT on early follicle growth, after MLT intake on PD10-21, mice were mated, then number of implanted embryos was counted (Fig. 4g). The results showed that the number of implanted embryos in MLT group was significantly smaller than that in the control group (P = 0.0354) and the embryo size was bigger than that in control group (P = 0.0000). In addition, the embryos in the MLT group showed unequal distribution on both uterine horns (Fig. 4h).

The above data indicated that exogenous MLT intake inhibits early follicle growth and atresia. To further explore the possible molecular mechanism, we performed RNA-sequencing (RNA-Seq). The volcano map of differential expressed genes was listed in Fig. 4i. Gene Ontology (GO) analysis showed that the differentially expressed genes were clustered into “Negative regulation of cell proliferation and differentiation” and “Regulation of cellular response to growth factor stimulus” (Fig. 4j). We further validated the accuracy of GO analysis. The result revealed that GC proliferation was suppressed after MLT intake, as PCNA, the proliferation marker, was downregulated in the MLT group (P = 0.029) (Fig. 4k, l). The Kyoto Encyclopedia of Genes and Genomes (KEGG) heatmap showed that the differentially expressed genes were mainly enriched in the typical pathways associated with folliculogenesis, including PI3K-AKT signaling, mitogen-activated protein kinase signaling, vascular endothelial growth factor signaling, and transforming growth factor-β signaling pathway (Fig. 4m, n). We then used western blotting to validate KEGG analysis and the result demonstrated that the phosphorylation of Akt significantly decreased in MLT group (P = 0.0023) (Fig. 4o).

SNAT-KO in mice accelerated the exhaustion of ovarian follicle reserve and age-related fertility decline

To evaluate the effect of endogenous MLT on early folliculogenesis, we prepared SNAT knockout (KO) mice, among which a total of 1440 bp genomic sequences in SNAT was deleted (Fig. 5a, b). In serum samples from wild-type mice, MLT absorption peak appeared in the chromatography, whereas in SNAT-KO mice, MLT absorption peak was invisible (Fig. 5c, d). Subsequently, we evaluated the effect of SNAT-KO on body development, visceral indexes, and blood biochemical indexes. The results showed that body development and visceral indexes (except spleen) were not affected by SNAT-KO (Supplementary Fig. 4a, b). In contrast, mean corpuscular volume (MCV), spleen weights, and the number of white blood cells (WBCs), and lymphocytes (Lym) were significantly reduced (P = 0.0062, 0.0012, 0.0295, and 0.0072, respectively); the number of neutrophils (Neu) significantly increased (P = 0.0114) (Supplementary Fig. 4c). The findings may demonstrate that MLT plays an important role in immune modulation. We then evaluated the effect of SNAT-KO on follicle activation and atresia. It was found that the number of activated follicles significantly increased (P = 0.039). After MLT supplementation, the increase in activated follicles caused by SNAT-KO can be completely rescued (P = 0.0000). Similarly, the number of atretic follicles in the SNAT-KO ovary significantly increased (P = 0.0064). After MLT intake, the number of atretic follicles in SNAT-KO mice decreased significantly (P = 0.0000) (Fig. 5e, f). Consistent with the changes in atretic follicles, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining experiment validated that apoptosis could be obviously observed in the ovary of both wild-type and SNAT-KO mice, but after MLT intake, apoptosis was reduced (Fig. 5g). We also examined the effect of SNAT-KO on the distribution of FOXO3 in oocytes. It was observed that SNAT-KO significantly enhanced the transport of FOXO3 to the ooplasm (P = 0.0008). In contrast, MLT intake effectively alleviated the effect of SNAT-KO on FOXO3 transport (P = 0.0000) (Fig. 5h, i). Furthermore, the data of western blotting also showed that MLT intake reduced the level of p-Akt in ovaries of SNAT-KO mice (Fig. 5j).

Fig. 5 — a Schematic diagram of *SNAT* knockout in the mouse genome. b The knockout mice were identified by PCR. c, d Detection of the MLT-synthetic ability of *SNAT*-KO mice. c The absorption peak of MLT appears in the positive control solution with MLT. d Representative chromatograms showed that the MLT absorption peak was visible in serum of wild-type mice but not in *SNAT-*KO mice. The positions indicated by arrows were MLT absorption peaks. e, f The effects of *SNAT*-KO and MLT intake on follicle activation and atresia. e Experimental design and representative photographs of H&E staining in each group, the scale bar = 100 µm. f The statistical chart of activated and atretic follicles (values are mean ± SEM). n = 3 biologically independent mice and 25 sections in each group were used for statistics. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. g Representative TUNEL staining of ovary samples in each group. The green dots represent apoptosis-positive cells. The scale bars are 100 µm in the original images and 20 µm in the enlarged images. h, i The effect of *SNAT*-KO and MLT intake on FOXO3 translocation in the oocytes. n = 2 biologically independent mice. h Representative photographs of immunofluorescent staining. The yellow arrows indicate cytosolic localization. The scale bars are 100 µm in the original images and 20 µm in the enlarged images. i The statistical charts of FOXO3 translocation (values are mean ± SEM). The number of sections used for statistics: wild-type n = 10; *SNAT*-KO n = 9; *SNAT*-KO + MLT n = 10. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. j The effect of *SNAT*-KO on PI3K-AKT pathways in ovaries. n = 2 biologically independent mice. The original western blottings can be viewed in Supplementary Fig. 7. k Representative photographs of offspring of female mice at the age of 8–9 months. l The effect of *SNAT*-KO on litter size (values are mean ± SEM). The number of mice used for mating: 2–3 M n = 10 (wild-type), 12 (*SNAT*-KO); 5–6 M n = 8 (wild-type), 12 (*SNAT*-KO); 8–9 M n = 9 (wild-type), 11 (*SNAT*-KO). Statistical significance was determined using two-tailed unpaired Student’s t-test. m, n Morphological features of ovaries from 11-month-old *SNAT*-KO and wild-type group were analyzed. n = 4 biologically independent mice. m Representative photographs of H&E staining in each group. The scale bar = 200 μm. n The statistical chart of early growing follicle (values are mean ± SEM), the number of sections used for statistics: wild-type n = 15; *SNAT*-KO n = 18. Statistical significance was determined using two-tailed unpaired Student’s t-test. o The expression of oocyte marker genes in *SNAT*-KO and wild-type groups (values are mean ± SEM). Normalization was performed using the proportion of reverse-transcribed RNA to total RNA. n = 3 biologically independent mice. Statistical significance was determined using two-tailed unpaired Student’s t-test. Significant differences are denoted by *P < 0.05 and **P < 0.01.

Then we analyzed the changes of litter size of mice with age after SNAT-KO. At the age of 2–3 months, SNAT-KO had no obvious effect on the litter size; at the age of 5–6 or 8–9 months, the litter size in SNAT-KO mice was significantly smaller than that in the wild type (P = 0.0398 and 0.0028, respectively) (Fig. 5k, l). The extent of ovarian aging can be reflected by the number of growing follicles in DOR, so we counted the number of growing follicles in the ovaries of 11-month-old mice. Compared with the wild type, the SNAT-KO mice showed a significant decrease in the number of follicles (P = 0.0018) (Fig. 5m, n). Nobox, Ddx4, and Figla, which were solely expressed by oocytes, were the marker genes that reflected the total number of oocytes in the ovary. Among those genes, the expression levels of Nobox and Figla in SNAT-KO ovary was lower than that in the wild type (P = 0.0156 and 0.0598, respectively) (Fig. 5o). The above phenotypic, histological, and molecular data collectively indicated that MLT deficiency accelerated ovarian aging by speeding up the age-related exhaustion in ovarian follicle reserve.

Long-term intake of excessive MLT did not disturb the reproductive rhythm and growth of mice

In the present study, both 1 and 15 mg kg⁻¹ MLT were effective in inhibiting follicle activation. However, it cannot be ignored that these doses are far above the physiological dose of MLT in the plasma⁴¹. Therefore, the safety of high-dose MLT was assessed in this section. We first studied the effect of MLT on mice physical growth. It was observed that long-term intake of 15 mg kg⁻¹ MLT neither affected body development nor visceral index (Fig. 6a, b). Subsequently, we evaluated the effect of MLT on the length of the estrous cycle, mating timings, pregnancy length, and labor timings. The results showed that all above indexes were not affected by long-term intake of 15 mg kg⁻¹ MLT (Fig. 6c–g). To evaluate the effect of MLT on the health condition of mice, the rectal temperature and blood biochemical indexes were measured. The rectal temperature did not change (Fig. 6h). The indexes that reflect the status of red blood cells (RBCs) and platelets were not affected, including those of RBC, corpuscular volume (MCV), hemoglobin (HGB), mean corpuscular HGB concentration (MCHC), and mean platelet volume (MPV). In contrast, the indexes of granulocytic amount (W-LCC) and intermediate cell amount (W-MCC), which reflect the level of immune cells, were decreased (P = 0.058 and 0.0136, respectively) (Fig. 6i).

Fig. 6 — a The effect of MLT intake on daily weight gain. n = 8 biologically independent mice. b The effect of MLT intake on visceral indexes. n = 10 (Con), 9 (MLT) biologically independent mice, respectively. c, d The effect of MLT intake on estrous cycle. c The chart of estrus records, red grids represent estrum, and the distance between two adjacent red grids represents the length of an estrus cycle. d The statistical chart of estrus cycle length. n = 10 biologically independent mice. e The effect of MLT intake on mating timings of female mice. n = 10 biologically independent mice. f The effect of MLT intake on pregnancy length. n = 10 biologically independent mice. g The effect of MLT intake on labor timings. n = 10 biologically independent mice. h The effect of MLT intake on body temperature. n = 9 (Con), 8 (MLT) biologically independent mice, respectively. i The effect of MLT on plasma biochemical indexes. n = 5 (Con), 4 (MLT) biologically independent mice. Statistical significance was determined using two-tailed unpaired Student’s t-test. Values are mean ± SEM. Significant differences are denoted by *P < 0.05. “ns” stands for P > 0.05, not significant.

Discussion

MLT is an extremely ancient hormone that can be traced back to the origin of life. At present, MLT has been evolved into a pleiotropic molecule²⁴. In the early photosynthetic prokaryotes, MLT presumably emerged primarily as an antioxidant and free radical scavenger⁴². For plants, MLT not only acts as an antioxidant but also as a signaling molecule to modulate pathways of ethylene, abscisic, jasmonic, and salicylic acids, and is involved in stress tolerance, pathogen defense, and delay of senescence⁴³. For animals, MLT is also a hormone and the hormonal property of MLT are apparent in the regulation of biological rhythm, sleep, inflammatory response, glucose metabolism, and tumor inhibition, beside the antioxidant effect^44–47. Based on the above characteristics, the identification of new physiological functions of MLT has long been a hot research topic in this field. Our study revealed that MLT inhibited follicle activation, growth, and atresia, which is crucial to understanding MLT’s delaying the female reproductive aging. Due to the lack of germline stem cells, female ovarian reserve cannot be replenished. The exhaustion of ovarian reserve is mainly realized through follicle activation, growth, and atresia. On one hand, the dormant follicles are awakened to the early growth stage, resulting in continuous decrease of PreOR. On the other hand, DOR formed by early growing follicles is always in a dynamic balance and the follicles are either in atresia or are freed from atresia by sufficient GTH, and translated to cyclic recruitment^48,49. Therefore, the inhibitory effect of MLT on follicle activation and growth can effectively reduce the depletion rate of ovarian reserve.

It is generally recognized that the PI3K-AKT-FOXO3 pathway controls follicle activation. Our study confirmed that MLT significantly inhibited PI3K-AKT pathway, which we believed the molecular mechanism of MLT inhibited follicle activation and growth. This study is not the first to report the inhibitory effect of MLT on PI3K-AKT pathway. For instance, a previous study found that MLT effectively inhibits the excessive activation of PI3K-AKT pathway by cisplatin, a commonly used chemotherapeutic drug, thereby protecting and stabilizing PreOR⁵⁰; MLT reduces inflammatory response in rheumatoid arthritis by inhibiting the PI3K-AKT pathway⁵¹; and MLT inhibits proliferation, invasion, and tumorigenesis of human bladder cancer cell by PI3K-AKT/mTOR/MMPs pathway⁵². Of note, our study can only conclude that MLT reduces follicle activation by inhibiting PI3K-AKT pathway, but whether it is direct or indirect inhibition is not clear yet. Unlike other common hormones, MLT can be mediated by either receptors or non-receptors⁵³. Here we showed that Mtnr1a was expressed at a low level in neonatal mouse ovaries and receptor inhibitor of Mtnr1a did not counteract the inhibitory effect of MLT on follicle activation (Supplementary Fig. 2). Therefore, the effect of MLT is at least not mediated by its transmembrane receptors. Previous studies on MLT’s receptors have confirmed that in addition to transmembrane receptors, there are numerous binding sites in the cytosol and in the nucleus, such as QR2, Calmodulin, GPR50, NQO2, RZR/RORα, VDR, etc.^54–57. Therefore, whether MLT modulates follicle activation and growth through these non-classical binding sites remains to be further investigated.

The exogenous addition (or ingestion) has been a major approach to evaluate the efficacy of MLT. For instance, MLT addition to the culture system can effectively improve the in vitro efficiency of oocyte maturation and embryo development⁵⁸; long-term oral intake of MLT protects against cholinergic degeneration in middle-aged mice of down syndrome⁵⁹; and long-term intake of exogenous MLT coupled with adequate sleep hygiene interventions may afford clinical benefits to children with neurodevelopmental disorders⁶⁰. However, drug safety and public opinion requires researchers to evaluate whether endogenous MLT plays the same role to exogenous MLT. Hence, we not only investigated the effect of exogenous MLT intake on early folliculogenesis, but the role of endogenous MLT. Cell culture indicated that GCs had the ability to secrete MLT (Fig. 1c), the loss of follicle reserve in MLT-deficient mice was faster than that of wild type, and phenotype of ovarian aging in middle age was more obvious than wild type (Fig. 5). The above results indicated that endogenous MLT was indeed involved in the regulation of early folliculogenesis and ovarian aging. Of note, we found that MLT deficiency did not significantly affect the fecundity of young mice. We speculate that, because MLT has many physiological functions, each of which cannot completely interrupt the related physiological process. MLT is more like a lubricant for life activities: with it, the activities run more smoothly; without it, the activities can still happen and adverse impact may take a long time to appear. It should also be noted that the KO mice in this study are of C57BL/6 strain, which has a point mutation in MLT synthesis gene, resulting in a comparatively lower MLT level than other strains⁶¹. We selected the KO mice of C57BL/6 strain, because in this strain, low MLT level was mainly found in the pineal gland but MLT levels in peripheral tissues were little different from other strains, such as the blood, thymus, and spleen⁶². Further, our final experimental results also confirmed that SNAT-KO in C57BL/6 mice accelerated the exhaustion of ovarian follicle reserve and affected immunological indexes.

The pineal gland has long been considered as the main organ for MLT synthesis. However, in recent years, some peripheral organs, such as the gastrointestinal tract, liver, and spleen, have also been reported to have the ability to synthesize MLT. Moreover, MLT synthesized by peripheral organs may have local functions different from that of the pineal origin⁶³. Therefore, the identification of new synthesis sites is crucial for a better understanding of MLT’s function. Previous studies have found that preovulatory follicular fluid has high levels of MLT⁶⁴, oocytes synthesize MLT through mitochondria to resist free radical⁶⁵, and SNAT and MT2 are expressed in abundance in human corpus luteum⁶⁶. Our study further demonstrated that GCs can synthesize MLT (Fig. 1c). Therefore, we can reasonably speculate that ovary is another MLT-secreting organ based on the above findings. Our study also demonstrated that MLT content in neonatal ovaries decreased with day age (Fig. 1e). Interestingly, however, MLT levels in the ovaries do not always decline. It has been reported that after the follicles enter GTH-dependent phase, GTH can upregulate MLT content in follicles before ovulation, and the increase of MLT content is involved in the modulation of luteinization⁶⁷. Therefore, we speculate that there may exist a mutual regulation mode mediated by MLT signaling between GTH-dependent follicles and GTH-independent follicles (i.e., primordial and early growing follicle) in the ovary. On one hand, primordial and early growing follicles provide sufficient supply of follicles for GTH-dependent folliculogenesis through activation and growth. On the other hand, GTH-dependent follicles secrete MLT so as to not only regulate its own development, but also inhibit follicle activation and growth in a negative feedback manner, helping to avoid overactivation of ovarian reserve.

With the further study of follicle activation, some substances (including rapamycin, bpV, ZCL278, Metformin, and 2-DG) have been listed as candidate drugs to delay ovarian aging or treat premature ovarian failure^68–72. For instance, rapamycin is highly recommended to be used in cancer chemotherapy for its strong inhibition of mTOR pathway. Recently, researchers have significantly prolonged the reproductive age of mice by short-term injection of rapamycin⁶⁹; as PTEN-PI3K-AKT pathway controls follicle activation, doctors have activated the follicles in vitro by adding the PTEN (phosphatase and tensin homolog) inhibitor bpV, which successfully allowed women who have premature ovarian failure gave birth to healthy children^70,71. However, the above methods also have limitations. During the phase of rapamycin treatment, experimental animals have estrous cycle disorder, sudden weight loss, etc.⁶⁹; the activity of the PTEN-PI3K-AKT pathway was enhanced in dividing tumor cells and stem cells, so either artificial inhibition or activation of those pathways will bring about unpredictable physiological risks. In contrast, MLT has an advantage in terms of safety and commercial MLT health products have already been available in the market. Further, as an endogenous molecule, MLT levels in follicular fluid of human are known to decrease with age⁷³. Our study demonstrated that 1-month MLT intake of high-dose had no significant effect on the estrous cycle, reproductive rhythm, and physical development of experimental animals (Fig. 6). Nevertheless, whether MLT has a potential to act as a human ovarian health product needs further investigation. In this study, the minimum dose of MLT to inhibit follicle activation is 1 mg kg⁻¹. If converted to a human dose, it is about 50 mg per day, but the current recommended maximum intake of commercial MLT products is 10 mg per day. Therefore, the dose of MLT intake of mice cannot be applied directly to humans. In addition, both MLT deficiency and long-term MLT intake had significant effects on the immunological indexes of experimental animals. For instance, the spleen weight of MLT-deficient mice was significantly lower than that of wild-type mice and the total amount of WBCs and the proportion of Lym in the blood were significantly reduced (Supplementary Fig. 4). Therefore, before using MLT as a health supplement to delay ovarian aging, it is necessary to evaluate the changes of human immune system function and the impact of such changes on health after long-term MLT intake.

In summary, this study demonstrates that endogenous MLT is involved in the regulation of early folliculogenesis and presents more insight into its roles in ovarian aging. In addition to its well-known antioxidant property, MLT as an endogenous molecule can also slow down ovarian aging by directly inhibiting follicle activation, growth, and atresia (Fig. 7). Furthermore, this study also provides direct evidence to confirm that the ovary is an organ that can synthesize MLT.

Fig. 7 — The depletion of ovarian follicle reserve is the direct cause of ovarian aging. MLT slows down the exhaustion of follicle reserve by inhibiting the activation, growth, and atresia of follicles in PreOR and DOR, thus delaying ovarian aging.

Methods

Animals

KM-strain mice (0–4 weeks old) were purchased from the Center for Animal Testing of Huazhong Agricultural University. SNAT-KO mice of C57BL/6 strain (0–11 months old) were obtained from Cyagen Biosciences (Guangzhou, China). The genotyping method of identifying SNAT-KO mice is as follows: Primer-1 was used for first PCR screening and the amplified fragment length was 627 bp; Primer-2 was used for PCR reconfirmation and the amplified fragment length was 669 bp. The reaction procedure was as follows: initial denaturation at 95 °C for 5 min, 40 cycles at 95 °C for 30 s, annealing at 60 °C for 30 s, then extension at 72 °C for 40 s, and a final elongation step at 72 °C for 5 min. The heterozygote mice have two amplicons, whereas the homozygote mice have only one amplicon. Primer sequences are listed in Supplementary Table 1. Mice were housed in a temperature-controlled facility (24 ± 2 °C) with constant 12 h light–dark cycles and were allowed access to food and water ad libitum. All experiments and animal handling were conducted in accordance with the institutional guidelines for animal experimentation after obtaining prior approval from the Institutional Animal Ethics Committee of Huazhong Agricultural University (HZAUMO-2017-049).

Experimental design and animal treatment

To assess the effect of MLT on follicle activation in vitro, the ovaries from mice at PD3 were cultured with MLT (Sigma, St. Louis, MO, USA) and then sectioned for histological analysis. To assess the effect of MLT on early follicle growth in vitro, the ovaries from mice at PD10 were cultured with MLT and then sectioned for histological analysis. To assess the effect of MLT on follicle activation in vivo, MLT were injected into mice from PD3. The ovaries at PD9 were sectioned for follicle counting and homogenized for the antioxidant assay. In addition, the ovaries at PD6 and PD9 were sectioned for immunofluorescence staining and ovaries at PD6 were homogenized for western blotting. To assess the effect of MLT on early follicle growth and atresia, MLT was injected into mice from PD10. The ovaries at PD15, 17, 19, and 21 were sectioned for histological analysis and ovaries at PD17 were collected for RNA-Seq and western blot analysis. To explore the effect of SNAT-KO on mice fecundity, the activated and atretic follicles of juvenile mice were evaluated. Adult mice were mated with wild-type males at the ages of 2–3 months, 5–6 months, and 8–9 months, respectively, and then the litter sizes were recorded. The ovaries from 11-month-old mice were collected for hematoxylin and eosin (H&E) staining and qRT-PCR assay. To investigate the effects of SNAT-KO on growth and health, neonatal mice were weighed from week 1 to 8. By adulthood, the weights of organs (heart, liver, spleen, and kidney) were measured and then divided by body weight to calculate visceral index. In addition, the blood samples were collected for biochemical index assay. To evaluate the effect of MLT on growth and health, 15 mg kg⁻¹ MLT was injected to mice, which lasted 30 days. The rectal temperature was recorded 4 days, 4 times; the body weight was recorded every day; on the last day, the weights of organs (heart, liver, spleen, and kidney) were measured to calculate visceral index and blood samples were collected for biochemical index assay. To examine the effect of MLT on reproductive rhythm, 15 mg kg⁻¹ MLT was injected every day and then estrum was recorded through vaginal smear, and mating timings were also recorded. To examine the effect of MLT on pregnant rhythm, 15 mg kg⁻¹ MLT was injected to mice when gestational age was above 12 days and then pregnancy lengths and labor timings were recorded.

Histomorphological analysis

Paraffin-embedded ovaries were sectioned for H&E staining (5 μm-thick paraffin sections). Thereafter, morphometric measurements were performed using digitalized images obtained directly from the microscope (Olympus BX53, Tokyo, Japan). Then morphometric parameters were measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Early growing follicles at primary (type 3a, b), secondary (type 4, 5a, 5b), SAF stages of development, and atretic follicles were counted in all sections based on the well-accepted standards established by the Pedersen and Peters⁷⁴ criterion. Briefly, type 3a, b follicles were characterized by a monolayer of cubic follicle cells surrounding an oocyte; type 4 follicles, two layers of follicle cells surrounding an oocyte; type 5a follicles have three layers of follicle cells; and type 5b follicles were characterized by many layers of follicle cells surrounding a fully grown oocyte, but the follicular antrum has not yet formed⁷⁴.

Ovary culture

Ovaries were collected on the designated time by microdissection in preheating phosphate-buffered saline. The ovaries from mice at PD3 were cultured on an insert (PICM0RG50, Millipore, USA) in six-well culture dishes in 1500 μL Dulbecco’s modified Eagle’s medium/Ham’s F12 nutrient mixture (DMEM/F12) (GIBCO, Life Technologies, USA) containing 0.1% bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA), ITS (1 : 100, Sigma, St. Louis, MO, USA), and Penicillin–Streptomycin Solution at an incubator (5% CO₂, 37 °C, and saturated humidity). The ovaries from mice at PD10 were cultured in the above medium with FSH (30 ng/ml, Sigma, St. Louis, MO, USA). Ovaries were cultured in either medium alone or medium with MLT or Luzindole (Sigma, St. Louis, MO, USA).

HPLC assay on MLT

A 1 ml syringe was used to puncture the follicles on the ovary surface to release GCs. Isolated GCs were incubated with 10⁻⁵ M 5-HT (Sigma, St. Louis, MO, USA) or culture medium alone (DMEM/F12 containing 0.1% BSA, 1.0% ITS) for 6 h to test their MLT-biosynthetic capacity. To verify whether SNAT-KO leads to loss of MLT in mice, the serum was collected for MLT assay. Ovaries were collected from mice at PD7, 9, 15, 17, and 19, respectively, and then homogenized immediately in 1 mL pre-cooling methylalcohol (Sigma, St. Louis, MO, USA) and centrifuged at 12,000 r.p.m. for 10 min at 4 °C. The supernatants were collected for MLT assay. The fragments of ovarian tissues were lysed with RIPA lysis buffer and total proteins were measured with BCA Protein Assay Kit (CWBiotech, Beijing, China) to normalize MLT level.

Chromatographic MLT separation was performed on Agilent 1260 Infinity II HPLC system (Agilent, America) equipped with a variable wavelength detector. The assay was carried out on InertSustain C18 column (250 mm × 4.6 mm, 5 μm, GL Sciences, Inc., Japan) with acetonitrile/ultrapure water (4/6) mixture flowing at a rate of 1 mL/min. Sample temperature, injection volume, and detection wavelength was 25 °C, 20 μL, and 222 nm, respectively. The MLT standard was purchased from Sigma, and was subsequently diluted to different concentrations for testing the standard curve. MLT in the samples was identified by its peak retention time compared to those of standards and were quantified based on peak height.

Measurements of antioxidant activity and lipid peroxidation

Ovaries of each group were collected and homogenized. The levels of SOD and T-AOC were measured by colorimetry. Blood samples of each group were collected and after clotting for 30 min, the serum was obtained by centrifugation at 3000 r.p.m. for 10 min and stored at −20 °C. The levels of GSH-PX, CAT, SOD, MDA, and T-AOC were measured by colorimetry. The detection was entrusted to Beijing North Institute of Biological Technology (Beijing, China). The detection kits were all purchased from Jiancheng Bioengineering Institute (Nanjing, China).

Superovulation, mating, and embryo count

Mice were injected with 5 I.U. PMSG (Ningbo Hormone Products Co., Ltd, Zhejiang, China) to stimulate follicle growth. A dose of 5 I.U. hCG (Ningbo Hormone Products Co., Ltd, Zhejiang, China) was then injected to trigger ovulation after 44 h. Subsequently, mice were killed, the reproductive organs were collected for visual observation, and ovulated oocytes were collected by puncturing the oviduct for quantitative analysis. Female mice were caged with adult males. The day of mating was recorded as the first day of gestation. Female mice were killed at 8.5 gestation day. Then the uteri were collected for photographic documentation, and the sizes and distribution of implanted embryos were measured.

Measurement of biochemical indexes

The whole blood samples in each group were collected in anti-coagulation tubes. Thereafter, the biochemical indexes were analyzed by a blood cell analyzer (pocH-100iV Diff, Sysmex, Japan). The detection was entrusted to the Veterinary Hospital of Huazhong Agricultural University. The test indexes included RBC count, corpuscular volume (MCV), HGB concentration, MCHC, MPV, WBC count, Lym, Neu, Lym count (W-SCC), granulocytic amount (W-LCC), and intermediate cell amount (W-MCC).

RNA-Seq and data analysis

The sequencing and data annotation were completed by Novogene Co., Ltd (Beijing China). Briefly, total RNAs were extracted using the Trizol reagent. Sequencing libraries were generated using NEBNext® UltraTM RNA Library Prep Kit for Illumina® (NEB, USA). To select cDNA fragments of preferentially 250–300 bp in length, the library fragments were purified with the AMPure XP system (Beckman Coulter, Beverly, USA). Then, the library quality was assessed on the Agilent Bioanalyzer 2100 system. Gene expression was normalized as the fragments per kilobase of exon per million fragments mapped (FPKM). FPKM values were calculated in each RefSeq gene for differential expression analysis. The P < 0.01 obtained with the Audic Claverie test was considered to be statistically significant. GO was used to annotate biological terms and the KEGG was used to find the associated pathways.

Immunohistochemistry and immunofluorescence

For immunohistochemistry, the sections were incubated with rabbit polyclonal antibodies (SNAT: 1 : 100; ab3505, Abcam; PCNA: 1 : 100, GT2253, Genetech, Shanghai, China) overnight at 4 °C; then, the sections were incubated with secondary antibody (goat anti-rabbit IgG: 1 : 200, G1213; goat anti-mouse IgG: 1 : 200, G1214, Servicebio Technology, Wuhan, China) for 1 h at 37 °C. After washing, sections were incubated with streptavidin–horseradish peroxidase (CWBiotech, Inc., Beijing, China) for 2 h. Target protein was visualized using DAB (Sigma-Aldrich, Shanghai, China) as the chromogen. For immunofluorescence staining, the sections were incubated with rabbit monoclonal antibodies (FOXO3a: 1 : 200, 2497 S, CST) overnight at 4 °C. Afterwards, the sections were incubated with fluorescent secondary antibody (goat anti-rabbit IgG: 1 : 200, GB21303, Servicebio Technology, Wuhan, China) for 50 min and subsequently stained with 4′,6-diamidino-2-phenylindole (DAPI) for 5 min. The images were obtained directly from ortho-fluorescence microscopy (Olympus, Co., Japan).

Western blotting

Total proteins were extracted with RIPA lysis buffer (Servicebio Technology, Wuhan, China). Thereafter, proteins were separated via SDS–polyacrylamide gel electrophoresis and then were subsequently transferred to polyvinylidene fluoride membranes. Subsequently, the membranes were incubated with primary antibodies for the following proteins: Akt (1 : 1000; 9272S, CST), p-Akt (Ser473; 1 : 1000; 4060S, CST), Rps6kb1 (1 : 1000; 9202S, CST), p-Rps6kb1 (Thr-389; 1 : 1000; 9205S, CST), Eif4ebp1 (1 : 1000; 9452S, CST), p-Eif4ebp1 (Ser-65; 1 : 1000; 9451S, CST), Yap (1 : 1000; 14074S, CST), p-Yap (Ser-127; 1 : 1000; 13008S, CST), Gapdh (1 : 2000; CW0100, CWBiotech, Beijing, China), and β-Actin (1 : 2000; CW0096, CWBiotech, Beijing, China). The membranes were then incubated with the corresponding secondary antibody (goat anti-rabbit IgG: 1 : 4000; BF03008, Biodragon-immunotech, Beijing, China; goat anti-mouse IgG: 1 : 4000, BF03001, Biodragon-immunotech, Beijing, China) for 2 h. Finally, the immunoblots were visualized with an ECL kit (CWBiotech, Beijing, China). The optical density of phosphorylated proteins (p-AKT, p-Rps6kb1, p-Eif4ebp1, and p-Yap) was measured by ImageJ software (National Institutes of Health, Bethesda, MD, USA) and normalized by the amount of the loading control on the same membrane.

PCR analysis

Total RNA was extracted using the Trizol reagent (Invitrogen, Inc., Carlsbad, CA, USA). Reverse transcription was carried out by using the PrimeScript^TM RT reagent kit with genome DNA Eraser (Takara Bio, Inc., Dalian, China). RT-PCR were run using a 2× Taq Plus PCR MasterMix (Tiangen Biotech, lnc., Beijing, China.). The reaction procedure was as follows: initial denaturation at 95 °C for 5 min, 40 cycles at 95 °C for 30 s, annealing at 64 °C for 30 s, then extension at 72 °C for 40 s, and a final elongation step at 72 °C for 5 min. Real-time quantitative PCR (qPCR) were run using a QuantiFast SYBR Green PCR Kit (Takara Bio, Inc., Dalian, China). The qPCR procedure was as follows: an initial step of 2 min at 50 °C, denaturation at 95 °C for 3 min; 35 cycles at 95 °C for 5 s, and 60 °C for 20 s, and a final elongation step at 72 °C for 3 min. Normalization was performed using the housekeeping gene Actb. The relative mRNA level was calculated by the 2^−△△ct method. When Nobox, Figla, and Ddx4 were used to evaluate the oocyte count in the ovary, the normalization was performed using the proportion of reverse-transcribed RNA to total RNA. Primer sequences are listed in Supplementary Table 1.

TUNEL staining

TUNEL staining was utilized to detect apoptosis in the ovaries from wild-type, SNAT-KO, and SNAT-KO + MLT groups according to the manufacturer’s protocol (In Situ Cell Death Detection Kit, Roche, Germany). Briefly, paraffin-embedded ovaries were subjected to routine 5 μm thickness sectioning. All sections were incubated in TUNEL reaction medium for 2 h at 37 °C in the dark. After the reaction was stopped, the sections were washed and stained with DAPI for 5 min. The TUNEL-positive cells in ovarian tissues from all the groups were observed using ortho-fluorescence microscopy (Olympus, Co., Japan).

Statistics and reproducibility

Statistical analyses were performed using GraphPad Prism 7 (GraphPad, San Diego, CA, USA). One-way analysis of variance followed by Tukey’s post hoc test and two-tailed unpaired Student’s t-test was used to analyze the statistical significance among multiple groups and between two groups, respectively. The comparison between the percentages used the χ²-test. P-value < 0.05 was considered statistically significant. The reproducibility was determined by using several biological replicates as indicated in the figure legends. Conclusions were not determined by a single detection technique, but by the combination of several experimental techniques from different perspectives. When performing histological analysis, we assigned three individuals who had not known grouping information to independently record and obtained similar results.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Supplementary information

Supplementary Information^{(3.7MB, docx)}

Supplementary Data 1^{(86.1KB, xlsx)}

Reporting Summary^{(277.2KB, pdf)}

Peer Review File^{(985KB, pdf)}

42003_2021_2042_MOESM5_ESM.pdf^{(4.1KB, pdf)}

Description of Additional Supplementary Files

Acknowledgements

This research was supported by the National Natural Science Foundation of China (31701301), the National Key Research and Development Program of China (2017YFD0501701), and the Fundamental Research Funds for the Central Universities of China (2662018PY037).

Author contributions

C.H. conceived the project, analyzed the data, and wrote the manuscript. C.Y. and Q.L. helped to design the study, performed the experiments, participated in analyzing the dataset, and writing the manuscript. Y.C., X.W., Z.R., and F.F. assisted with sample collection and data analysis, and revised the manuscript. J.X., G.L., X.L., and L.Y. reviewed the manuscript and provided substantial advice through experimental work. All authors read though the manuscript and approved the final version.

Data availability

The RNA-sequencing data are openly available in Zenodo (10.5281/zenodo.3365397)⁷⁵. Source data underlying plots shown in figures are provided in Supplementary Data 1. All other data are available upon reasonable request.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Chan Yang, Qinghua Liu.

Supplementary information

The online version contains supplementary material available at 10.1038/s42003-021-02042-z.

References

1.Laisk T, et al. Demographic and evolutionary trends in ovarian function and aging. Hum. Reprod. Update. 2019;25:34–50. doi: 10.1093/humupd/dmy031. [DOI] [PubMed] [Google Scholar]
2.Brar V, et al. Sex-specific effects of cardiovascular risk factors on endothelium-dependent dilation and endothelin activity in middle-aged women and men. PLoS ONE. 2015;10:e0121810. doi: 10.1371/journal.pone.0121810. [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Dorobantu M, Onciul S, Tautu OF, Cenko E. Hypertension and ischemic heart disease in women. Curr. Pharm. Des. 2016;22:3885–3892. doi: 10.2174/1381612822666160414142426. [DOI] [PubMed] [Google Scholar]
4.Onat A, Karadeniz Y, Tusun E, Yüksel H, Kaya A. Advances in understanding gender difference in cardiometabolic disease risk. Expert Rev. Cardiovasc. Ther. 2016;14:513–523. doi: 10.1586/14779072.2016.1150782. [DOI] [PubMed] [Google Scholar]
5.Stevenson JC. A woman’s journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. Maturitas. 2011;70:197–205. doi: 10.1016/j.maturitas.2011.05.017. [DOI] [PubMed] [Google Scholar]
6.Wise PM, Krajnak KM, Kashon ML. Menopause: the aging of multiple pacemakers. Science. 1996;273:67–70. doi: 10.1126/science.273.5271.67. [DOI] [PubMed] [Google Scholar]
7.Wagner M, et al. Single-cell analysis of human ovarian cortex identifies distinct cell populations but no oogonial stem cells. Nat. Commun. 2020;11:1147. doi: 10.1038/s41467-020-14936-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Zhang H, et al. Adult human and mouse ovaries lack DDX4-expressing functional oogonial stem cells. Nat. Med. 2015;21:1116–1118. doi: 10.1038/nm.3775. [DOI] [PubMed] [Google Scholar]
9.Fortune JE. The early stages of follicular development: activation of primordial follicles and growth of preantral follicles. Anim. Reprod. Sci. 2003;78:135–163. doi: 10.1016/S0378-4320(03)00088-5. [DOI] [PubMed] [Google Scholar]
10.Wang C, Zhou B, Xia G. Mechanisms controlling germline cyst breakdown and primordial follicle formation. Cell. Mol. life Sci. 2017;74:2547–2566. doi: 10.1007/s00018-017-2480-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr. Rev. 2009;30:465–493. doi: 10.1210/er.2009-0006. [DOI] [PubMed] [Google Scholar]
12.Hsueh AJ, Kawamura K, Cheng Y, Fauser BC. Intraovarian control of early folliculogenesis. Endocr. Rev. 2015;36:1–24. doi: 10.1210/er.2014-1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Monniaux D, et al. The ovarian reserve of primordial follicles and the dynamic reserve of antral growing follicles: what is the link? Biol. Reprod. 2014;90:85. doi: 10.1095/biolreprod.113.117077. [DOI] [PubMed] [Google Scholar]
14.Scaramuzzi RJ, et al. Regulation of folliculogenesis and the determination of ovulation rate in ruminants. Reprod. Fertil. Dev. 2011;23:444–467. doi: 10.1071/RD09161. [DOI] [PubMed] [Google Scholar]
15.Ginther OJ, et al. Effects of age on follicle and hormone dynamics during the oestrous cycle in mares. Reprod. Fertil. Dev. 2008;20:955–963. doi: 10.1071/RD08121. [DOI] [PubMed] [Google Scholar]
16.Scheffer GJ, et al. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil. Steril. 1999;72:845–851. doi: 10.1016/S0015-0282(99)00396-9. [DOI] [PubMed] [Google Scholar]
17.Craig J, et al. Gonadotropin and intra-ovarian signals regulating follicle development and atresia: the delicate balance between life and death. Front. Biosci. 2007;12:3628–3639. doi: 10.2741/2339. [DOI] [PubMed] [Google Scholar]
18.Matsuda F, Inoue N, Manabe N, Ohkura S. Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J. Reprod. Dev. 2012;58:44–50. doi: 10.1262/jrd.2011-012. [DOI] [PubMed] [Google Scholar]
19.Chun SY, et al. Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival factor. Endocrinology. 1996;137:1447–14561. doi: 10.1210/endo.137.4.8625923. [DOI] [PubMed] [Google Scholar]
20.Lim J, Luderer U. Oxidative damage increases and antioxidant gene expression decreases with aging in the mouse ovary. Biol. Reprod. 2011;84:775–782. doi: 10.1095/biolreprod.110.088583. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Wang S, et al. Single-cell transcriptomic atlas of primate ovarian. Aging Cell. 2020;180:585–600. doi: 10.1016/j.cell.2020.01.009. [DOI] [PubMed] [Google Scholar]
22.Zhang J, et al. Can ovarian aging be delayed by pharmacological strategies? Aging. 2019;11:817–832. doi: 10.18632/aging.101784. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Reiter RJ, et al. Melatonin as an antioxidant: under promises but over delivers. J. Pineal Res. 2016;61:253–2781. doi: 10.1111/jpi.12360. [DOI] [PubMed] [Google Scholar]
24.Zhao D, et al. Melatonin synthesis and function: evolutionary history in animals and plants. Front. Endocrinol. 2019;10:2491. doi: 10.3389/fendo.2019.00249. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Batnasan E, Xie S, Zhang Q, Li Y. Observation of parthanatos involvement in diminished ovarian reserve patients and melatonin’s protective function through inhibiting ADP-ribose (PAR) expression and preventing AIF translocation into the nucleus. Reprod. Sci. 2020;27:75–86. doi: 10.1007/s43032-019-00005-8. [DOI] [PubMed] [Google Scholar]
26.Hao EY, et al. Melatonin regulates the ovarian function and enhances follicle growth in aging laying hens via activating the mammalian target of rapamycin pathway. Poult. Sci. 2020;99:2185–2195. doi: 10.1016/j.psj.2019.11.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Song C, et al. Melatonin improves age-induced fertility decline and attenuates ovarian mitochondrial oxidative stress in mice. Sci. Rep. 2016;6:35165. doi: 10.1038/srep35165. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Tamura, H. et al. Importance of melatonin in assisted reproductive technology and ovarian aging. Int. J. Mol. Sci. 21, 1135 (2020). [DOI] [PMC free article] [PubMed]
29.Tamura, H. et al. Long-term melatonin treatment delays ovarian aging. J. Pineal Res. 62, e12381 (2017). [DOI] [PubMed]
30.Yang Y, Cheung HH, Zhang C, Wu J, Chan WY. Melatonin as potential targets for delaying ovarian aging. Curr. Drug Targets. 2019;20:16–28. doi: 10.2174/1389450119666180828144843. [DOI] [PubMed] [Google Scholar]
31.Finley, C. M., Gorman, M. R., Tuthill, C. R. & Zucker, I. Long-term reproductive effects of a single long day in the Siberian hamster (Phodopus sungorus). J. Biol. Rhythms10, 33–41 (1995). [DOI] [PubMed]
32.Place NJ, Tuthill CR, Schoomer EE, Tramontin AD, Zucker I. Short day lengths delay reproductive aging. Biol. Reprod. 2004;71:987–992. doi: 10.1095/biolreprod.104.029900. [DOI] [PubMed] [Google Scholar]
33.Fernández BE, Díaz E, Fernández C, Núñez P, Díaz B. Ovarian aging: melatonin regulation of the cytometric and endocrine evolutive pattern. Curr. Aging Sci. 2013;6:1–71. doi: 10.2174/1874609811306010001. [DOI] [PubMed] [Google Scholar]
34.Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp. Gerontol. 2001;36:297–3101. doi: 10.1016/S0531-5565(00)00217-5. [DOI] [PubMed] [Google Scholar]
35.Reiter, R. J. et al. Mitochondria: central organelles for melatonin’s antioxidant and anti-aging actions. Molecules23, 509 (2018). [DOI] [PMC free article] [PubMed]
36.Reddy P, et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2008;319:611–613. doi: 10.1126/science.1152257. [DOI] [PubMed] [Google Scholar]
37.Zhang H, et al. Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. Curr. Biol. 2014;24:2501–2508. doi: 10.1016/j.cub.2014.09.023. [DOI] [PubMed] [Google Scholar]
38.Grosbois J, Demeestere I. Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation. Hum. Reprod. 2018;33:1705–1714. doi: 10.1093/humrep/dey250. [DOI] [PubMed] [Google Scholar]
39.Hsueh AJW, Kawamura K. Hippo signaling disruption and ovarian follicle activation in infertile patients. Fertil. Steril. 2020;114:458–464. doi: 10.1016/j.fertnstert.2020.07.031. [DOI] [PubMed] [Google Scholar]
40.Lo Sardo, F., Muti, P., Blandino, G. & Strano, S. Melatonin and Hippo pathway: is there existing cross-talk? Int. J. Mol. Sci. 18, 1913 (2017). [DOI] [PMC free article] [PubMed]
41.Pang SF, et al. Fluctuation of blood melatonin concentrations with age: result of changes in pineal melatonin secretion, body growth, and aging. J. Pineal Res. 1990;8:179–1921. doi: 10.1111/j.1600-079X.1990.tb00678.x. [DOI] [PubMed] [Google Scholar]
42.Tan DX, et al. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes. J. Pineal Res. 2013;54:127–1381. doi: 10.1111/jpi.12026. [DOI] [PubMed] [Google Scholar]
43.Hardeland R. Melatonin in plants - diversity of levels and multiplicity of functions. Front. Plant Sci. 2016;7:198. doi: 10.3389/fpls.2016.00198. [DOI] [PMC free article] [PubMed] [Google Scholar]
44.Bondy, S. C. & Campbell, A. Mechanisms underlying tumor suppressive properties of melatonin. Int. J. Mol. Sci. 19, 2205 (2018). [DOI] [PMC free article] [PubMed]
45.Carrillo-Vico A, et al. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Invest. Drugs. 2006;7:423–431. [PubMed] [Google Scholar]
46.Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat. Rev. Endocrinol. 2019;15:105–125. doi: 10.1038/s41574-018-0130-1. [DOI] [PubMed] [Google Scholar]
47.Najafi M, et al. Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacology. 2017;25:403–413. doi: 10.1007/s10787-017-0332-5. [DOI] [PubMed] [Google Scholar]
48.Aerts JM, Bols PE. Ovarian follicular dynamics. A review with emphasis on the bovine species. Part II: antral development, exogenous influence and future prospects. Reprod. Domest. Anim. 2010;45:180–1871. doi: 10.1111/j.1439-0531.2008.01298.x. [DOI] [PubMed] [Google Scholar]
49.Aerts JM, Bols PE. Ovarian follicular dynamics: a review with emphasis on the bovine species. Part I: folliculogenesis and pre-antral follicle development. Reprod. Domest. Anim. 2010;45:171–17910. doi: 10.1111/j.1439-0531.2008.01302.x. [DOI] [PubMed] [Google Scholar]
50.Jang H, et al. Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary. J. Pineal Res. 2016;60:336–34710. doi: 10.1111/jpi.12316. [DOI] [PubMed] [Google Scholar]
51.Huang CC, et al. Melatonin attenuates TNF-α and IL-1β expression in synovial fibroblasts and diminishes cartilage degradation: Implications for the treatment of rheumatoid arthritis. J. Pineal Res. 2019;66:e125601. doi: 10.1111/jpi.12560. [DOI] [PubMed] [Google Scholar]
52.Chen YT, et al. Jagged2 progressively increased expression from stage I to III of bladder cancer and melatonin-mediated downregulation of Notch/Jagged2 suppresses the bladder tumorigenesis via inhibiting PI3K/AKT/mTOR/MMPs signaling. Int. J. Biol. Sci. 2020;16:2648–2662. doi: 10.7150/ijbs.48358. [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Reiter RJ, et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv. Med. Sci. 2007;52:11–28. [PubMed] [Google Scholar]
54.Benítez-King G, Huerto-Delgadillo L, Antón-Tay F. Binding of 3H-melatonin to calmodulin. Life Sci. 1993;53:201–207. doi: 10.1016/0024-3205(93)90670-X. [DOI] [PubMed] [Google Scholar]
55.Boutin JA, Ferry G. Is there sufficient evidence that the melatonin binding site MT(3) is quinone reductase 2? J. Pharmacol. Exp. therapeutics. 2019;368:59–65. doi: 10.1124/jpet.118.253260. [DOI] [PubMed] [Google Scholar]
56.Emet M, et al. A review of melatonin, its receptors and drugs. Eurasia. J. Med. 2016;48:135–141. doi: 10.5152/eurasianjmed.2015.0267. [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Fang N, et al. Identification of a novel melatonin-binding nuclear receptor: vitamin D receptor. J. Pineal Res. 2020;68:e12618. doi: 10.1111/jpi.12618. [DOI] [PubMed] [Google Scholar]
58.Genario R, Morello E, Bueno AA, Santos HO. The usefulness of melatonin in the field of obstetrics and gynecology. Pharmacol. Res. 2019;147:104337. doi: 10.1016/j.phrs.2019.104337. [DOI] [PubMed] [Google Scholar]
59.Corrales A, et al. Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J. Pineal Res. 2013;54:346–358. doi: 10.1111/jpi.12037. [DOI] [PubMed] [Google Scholar]
60.Yuge K, et al. Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders. BMC Psychiatry. 2020;20:445. doi: 10.1186/s12888-020-02847-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
61.von Gall C, et al. Transcription factor dynamics and neuroendocrine signalling in the mouse pineal gland: a comparative analysis of melatonin-deficient C57BL mice and melatonin-proficient C3H mice. Eur. J. Neurosci. 2000;12:964–972. doi: 10.1046/j.1460-9568.2000.00990.x. [DOI] [PubMed] [Google Scholar]
62.Gómez-Corvera A, et al. Evidence of immune system melatonin production by two pineal melatonin deficient mice, C57BL/6 and Swiss strains. J. Pineal Res. 2009;47:15–221. doi: 10.1111/j.1600-079X.2009.00683.x. [DOI] [PubMed] [Google Scholar]
63.Acuña-Castroviejo D, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell. Mol. Life Sci. 2014;71:2997–30251. doi: 10.1007/s00018-014-1579-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
64.Zhang M, Lu Y, Chen Y, Zhang Y, Xiong B. Insufficiency of melatonin in follicular fluid is a reversible cause for advanced maternal age-related aneuploidy in oocytes. Redox Biol. 2020;28:101327. doi: 10.1016/j.redox.2019.101327. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.He, C. et al. Mitochondria synthesize melatonin to ameliorate its function and improve mice oocyte’s quality under in vitro conditions. Int. J. Mol. Sci. 17, 939 (2016). [DOI] [PMC free article] [PubMed]
66.Scarinci E, et al. “Hormone of darkness” and human reproductive process: direct regulatory role of melatonin in human corpus luteum. J. Endocrinol. Investig. 2019;42:1191–1197. doi: 10.1007/s40618-019-01036-3. [DOI] [PubMed] [Google Scholar]
67.He C, et al. Melatonin and its receptor MT1 are involved in the downstream reaction to luteinizing hormone and participate in the regulation of luteinization in different species. J. Pineal Res. 2016;61:279–290. doi: 10.1111/jpi.12345. [DOI] [PubMed] [Google Scholar]
68.Barilovits SJ, et al. Characterization of a mechanism to inhibit ovarian follicle activation. Fertil. Steril. 2014;101:1450–1457. doi: 10.1016/j.fertnstert.2014.01.025. [DOI] [PubMed] [Google Scholar]
69.Dou X, et al. Short-term rapamycin treatment increases ovarian lifespan in young and middle-aged female mice. Aging Cell. 2017;16:825–836. doi: 10.1111/acel.12617. [DOI] [PMC free article] [PubMed] [Google Scholar]
70.Kawamura K, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc. Natl. Acad. Sci. USA. 2013;110:17474–17479. doi: 10.1073/pnas.1312830110. [DOI] [PMC free article] [PubMed] [Google Scholar]
71.Li J, et al. Activation of dormant ovarian follicles to generate mature eggs. Proc. Natl. Acad. Sci. USA. 2010;107:10280–10284. doi: 10.1073/pnas.1001198107. [DOI] [PMC free article] [PubMed] [Google Scholar]
72.Qin X, et al. Metformin prevents murine ovarian aging. Aging. 2019;11:3785–3794. doi: 10.18632/aging.102016. [DOI] [PMC free article] [PubMed] [Google Scholar]
73.Tong J, et al. Melatonin levels in follicular fluid as markers for IVF outcomes and predicting ovarian reserve. Reproduction. 2017;153:443–451. doi: 10.1530/REP-16-0641. [DOI] [PubMed] [Google Scholar]
74.Pedersen T, Peters H. Proposal for a classification of oocytes and follicles in the mouse ovary. J. Reprod. Fertil. 1968;17:555–557. doi: 10.1530/jrf.0.0170555. [DOI] [PubMed] [Google Scholar]
75.Yang, C. RNA-Seq data for mice ovaries [Data set] (Zenodo, 2019).

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information^{(3.7MB, docx)}

Supplementary Data 1^{(86.1KB, xlsx)}

Reporting Summary^{(277.2KB, pdf)}

Peer Review File^{(985KB, pdf)}

42003_2021_2042_MOESM5_ESM.pdf^{(4.1KB, pdf)}

Description of Additional Supplementary Files

Data Availability Statement

[CR1] 1.Laisk T, et al. Demographic and evolutionary trends in ovarian function and aging. Hum. Reprod. Update. 2019;25:34–50. doi: 10.1093/humupd/dmy031. [DOI] [PubMed] [Google Scholar]

[CR2] 2.Brar V, et al. Sex-specific effects of cardiovascular risk factors on endothelium-dependent dilation and endothelin activity in middle-aged women and men. PLoS ONE. 2015;10:e0121810. doi: 10.1371/journal.pone.0121810. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR3] 3.Dorobantu M, Onciul S, Tautu OF, Cenko E. Hypertension and ischemic heart disease in women. Curr. Pharm. Des. 2016;22:3885–3892. doi: 10.2174/1381612822666160414142426. [DOI] [PubMed] [Google Scholar]

[CR4] 4.Onat A, Karadeniz Y, Tusun E, Yüksel H, Kaya A. Advances in understanding gender difference in cardiometabolic disease risk. Expert Rev. Cardiovasc. Ther. 2016;14:513–523. doi: 10.1586/14779072.2016.1150782. [DOI] [PubMed] [Google Scholar]

[CR5] 5.Stevenson JC. A woman’s journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. Maturitas. 2011;70:197–205. doi: 10.1016/j.maturitas.2011.05.017. [DOI] [PubMed] [Google Scholar]

[CR6] 6.Wise PM, Krajnak KM, Kashon ML. Menopause: the aging of multiple pacemakers. Science. 1996;273:67–70. doi: 10.1126/science.273.5271.67. [DOI] [PubMed] [Google Scholar]

[CR7] 7.Wagner M, et al. Single-cell analysis of human ovarian cortex identifies distinct cell populations but no oogonial stem cells. Nat. Commun. 2020;11:1147. doi: 10.1038/s41467-020-14936-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR8] 8.Zhang H, et al. Adult human and mouse ovaries lack DDX4-expressing functional oogonial stem cells. Nat. Med. 2015;21:1116–1118. doi: 10.1038/nm.3775. [DOI] [PubMed] [Google Scholar]

[CR9] 9.Fortune JE. The early stages of follicular development: activation of primordial follicles and growth of preantral follicles. Anim. Reprod. Sci. 2003;78:135–163. doi: 10.1016/S0378-4320(03)00088-5. [DOI] [PubMed] [Google Scholar]

[CR10] 10.Wang C, Zhou B, Xia G. Mechanisms controlling germline cyst breakdown and primordial follicle formation. Cell. Mol. life Sci. 2017;74:2547–2566. doi: 10.1007/s00018-017-2480-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR11] 11.Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr. Rev. 2009;30:465–493. doi: 10.1210/er.2009-0006. [DOI] [PubMed] [Google Scholar]

[CR12] 12.Hsueh AJ, Kawamura K, Cheng Y, Fauser BC. Intraovarian control of early folliculogenesis. Endocr. Rev. 2015;36:1–24. doi: 10.1210/er.2014-1020. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR13] 13.Monniaux D, et al. The ovarian reserve of primordial follicles and the dynamic reserve of antral growing follicles: what is the link? Biol. Reprod. 2014;90:85. doi: 10.1095/biolreprod.113.117077. [DOI] [PubMed] [Google Scholar]

[CR14] 14.Scaramuzzi RJ, et al. Regulation of folliculogenesis and the determination of ovulation rate in ruminants. Reprod. Fertil. Dev. 2011;23:444–467. doi: 10.1071/RD09161. [DOI] [PubMed] [Google Scholar]

[CR15] 15.Ginther OJ, et al. Effects of age on follicle and hormone dynamics during the oestrous cycle in mares. Reprod. Fertil. Dev. 2008;20:955–963. doi: 10.1071/RD08121. [DOI] [PubMed] [Google Scholar]

[CR16] 16.Scheffer GJ, et al. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil. Steril. 1999;72:845–851. doi: 10.1016/S0015-0282(99)00396-9. [DOI] [PubMed] [Google Scholar]

[CR17] 17.Craig J, et al. Gonadotropin and intra-ovarian signals regulating follicle development and atresia: the delicate balance between life and death. Front. Biosci. 2007;12:3628–3639. doi: 10.2741/2339. [DOI] [PubMed] [Google Scholar]

[CR18] 18.Matsuda F, Inoue N, Manabe N, Ohkura S. Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. J. Reprod. Dev. 2012;58:44–50. doi: 10.1262/jrd.2011-012. [DOI] [PubMed] [Google Scholar]

[CR19] 19.Chun SY, et al. Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival factor. Endocrinology. 1996;137:1447–14561. doi: 10.1210/endo.137.4.8625923. [DOI] [PubMed] [Google Scholar]

[CR20] 20.Lim J, Luderer U. Oxidative damage increases and antioxidant gene expression decreases with aging in the mouse ovary. Biol. Reprod. 2011;84:775–782. doi: 10.1095/biolreprod.110.088583. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR21] 21.Wang S, et al. Single-cell transcriptomic atlas of primate ovarian. Aging Cell. 2020;180:585–600. doi: 10.1016/j.cell.2020.01.009. [DOI] [PubMed] [Google Scholar]

[CR22] 22.Zhang J, et al. Can ovarian aging be delayed by pharmacological strategies? Aging. 2019;11:817–832. doi: 10.18632/aging.101784. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR23] 23.Reiter RJ, et al. Melatonin as an antioxidant: under promises but over delivers. J. Pineal Res. 2016;61:253–2781. doi: 10.1111/jpi.12360. [DOI] [PubMed] [Google Scholar]

[CR24] 24.Zhao D, et al. Melatonin synthesis and function: evolutionary history in animals and plants. Front. Endocrinol. 2019;10:2491. doi: 10.3389/fendo.2019.00249. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR25] 25.Batnasan E, Xie S, Zhang Q, Li Y. Observation of parthanatos involvement in diminished ovarian reserve patients and melatonin’s protective function through inhibiting ADP-ribose (PAR) expression and preventing AIF translocation into the nucleus. Reprod. Sci. 2020;27:75–86. doi: 10.1007/s43032-019-00005-8. [DOI] [PubMed] [Google Scholar]

[CR26] 26.Hao EY, et al. Melatonin regulates the ovarian function and enhances follicle growth in aging laying hens via activating the mammalian target of rapamycin pathway. Poult. Sci. 2020;99:2185–2195. doi: 10.1016/j.psj.2019.11.040. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR27] 27.Song C, et al. Melatonin improves age-induced fertility decline and attenuates ovarian mitochondrial oxidative stress in mice. Sci. Rep. 2016;6:35165. doi: 10.1038/srep35165. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR28] 28.Tamura, H. et al. Importance of melatonin in assisted reproductive technology and ovarian aging. Int. J. Mol. Sci. 21, 1135 (2020). [DOI] [PMC free article] [PubMed]

[CR29] 29.Tamura, H. et al. Long-term melatonin treatment delays ovarian aging. J. Pineal Res. 62, e12381 (2017). [DOI] [PubMed]

[CR30] 30.Yang Y, Cheung HH, Zhang C, Wu J, Chan WY. Melatonin as potential targets for delaying ovarian aging. Curr. Drug Targets. 2019;20:16–28. doi: 10.2174/1389450119666180828144843. [DOI] [PubMed] [Google Scholar]

[CR31] 31.Finley, C. M., Gorman, M. R., Tuthill, C. R. & Zucker, I. Long-term reproductive effects of a single long day in the Siberian hamster (Phodopus sungorus). J. Biol. Rhythms10, 33–41 (1995). [DOI] [PubMed]

[CR32] 32.Place NJ, Tuthill CR, Schoomer EE, Tramontin AD, Zucker I. Short day lengths delay reproductive aging. Biol. Reprod. 2004;71:987–992. doi: 10.1095/biolreprod.104.029900. [DOI] [PubMed] [Google Scholar]

[CR33] 33.Fernández BE, Díaz E, Fernández C, Núñez P, Díaz B. Ovarian aging: melatonin regulation of the cytometric and endocrine evolutive pattern. Curr. Aging Sci. 2013;6:1–71. doi: 10.2174/1874609811306010001. [DOI] [PubMed] [Google Scholar]

[CR34] 34.Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp. Gerontol. 2001;36:297–3101. doi: 10.1016/S0531-5565(00)00217-5. [DOI] [PubMed] [Google Scholar]

[CR35] 35.Reiter, R. J. et al. Mitochondria: central organelles for melatonin’s antioxidant and anti-aging actions. Molecules23, 509 (2018). [DOI] [PMC free article] [PubMed]

[CR36] 36.Reddy P, et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2008;319:611–613. doi: 10.1126/science.1152257. [DOI] [PubMed] [Google Scholar]

[CR37] 37.Zhang H, et al. Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. Curr. Biol. 2014;24:2501–2508. doi: 10.1016/j.cub.2014.09.023. [DOI] [PubMed] [Google Scholar]

[CR38] 38.Grosbois J, Demeestere I. Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation. Hum. Reprod. 2018;33:1705–1714. doi: 10.1093/humrep/dey250. [DOI] [PubMed] [Google Scholar]

[CR39] 39.Hsueh AJW, Kawamura K. Hippo signaling disruption and ovarian follicle activation in infertile patients. Fertil. Steril. 2020;114:458–464. doi: 10.1016/j.fertnstert.2020.07.031. [DOI] [PubMed] [Google Scholar]

[CR40] 40.Lo Sardo, F., Muti, P., Blandino, G. & Strano, S. Melatonin and Hippo pathway: is there existing cross-talk? Int. J. Mol. Sci. 18, 1913 (2017). [DOI] [PMC free article] [PubMed]

[CR41] 41.Pang SF, et al. Fluctuation of blood melatonin concentrations with age: result of changes in pineal melatonin secretion, body growth, and aging. J. Pineal Res. 1990;8:179–1921. doi: 10.1111/j.1600-079X.1990.tb00678.x. [DOI] [PubMed] [Google Scholar]

[CR42] 42.Tan DX, et al. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes. J. Pineal Res. 2013;54:127–1381. doi: 10.1111/jpi.12026. [DOI] [PubMed] [Google Scholar]

[CR43] 43.Hardeland R. Melatonin in plants - diversity of levels and multiplicity of functions. Front. Plant Sci. 2016;7:198. doi: 10.3389/fpls.2016.00198. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR44] 44.Bondy, S. C. & Campbell, A. Mechanisms underlying tumor suppressive properties of melatonin. Int. J. Mol. Sci. 19, 2205 (2018). [DOI] [PMC free article] [PubMed]

[CR45] 45.Carrillo-Vico A, et al. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Invest. Drugs. 2006;7:423–431. [PubMed] [Google Scholar]

[CR46] 46.Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat. Rev. Endocrinol. 2019;15:105–125. doi: 10.1038/s41574-018-0130-1. [DOI] [PubMed] [Google Scholar]

[CR47] 47.Najafi M, et al. Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacology. 2017;25:403–413. doi: 10.1007/s10787-017-0332-5. [DOI] [PubMed] [Google Scholar]

[CR48] 48.Aerts JM, Bols PE. Ovarian follicular dynamics. A review with emphasis on the bovine species. Part II: antral development, exogenous influence and future prospects. Reprod. Domest. Anim. 2010;45:180–1871. doi: 10.1111/j.1439-0531.2008.01298.x. [DOI] [PubMed] [Google Scholar]

[CR49] 49.Aerts JM, Bols PE. Ovarian follicular dynamics: a review with emphasis on the bovine species. Part I: folliculogenesis and pre-antral follicle development. Reprod. Domest. Anim. 2010;45:171–17910. doi: 10.1111/j.1439-0531.2008.01302.x. [DOI] [PubMed] [Google Scholar]

[CR50] 50.Jang H, et al. Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary. J. Pineal Res. 2016;60:336–34710. doi: 10.1111/jpi.12316. [DOI] [PubMed] [Google Scholar]

[CR51] 51.Huang CC, et al. Melatonin attenuates TNF-α and IL-1β expression in synovial fibroblasts and diminishes cartilage degradation: Implications for the treatment of rheumatoid arthritis. J. Pineal Res. 2019;66:e125601. doi: 10.1111/jpi.12560. [DOI] [PubMed] [Google Scholar]

[CR52] 52.Chen YT, et al. Jagged2 progressively increased expression from stage I to III of bladder cancer and melatonin-mediated downregulation of Notch/Jagged2 suppresses the bladder tumorigenesis via inhibiting PI3K/AKT/mTOR/MMPs signaling. Int. J. Biol. Sci. 2020;16:2648–2662. doi: 10.7150/ijbs.48358. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR53] 53.Reiter RJ, et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv. Med. Sci. 2007;52:11–28. [PubMed] [Google Scholar]

[CR54] 54.Benítez-King G, Huerto-Delgadillo L, Antón-Tay F. Binding of 3H-melatonin to calmodulin. Life Sci. 1993;53:201–207. doi: 10.1016/0024-3205(93)90670-X. [DOI] [PubMed] [Google Scholar]

[CR55] 55.Boutin JA, Ferry G. Is there sufficient evidence that the melatonin binding site MT(3) is quinone reductase 2? J. Pharmacol. Exp. therapeutics. 2019;368:59–65. doi: 10.1124/jpet.118.253260. [DOI] [PubMed] [Google Scholar]

[CR56] 56.Emet M, et al. A review of melatonin, its receptors and drugs. Eurasia. J. Med. 2016;48:135–141. doi: 10.5152/eurasianjmed.2015.0267. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR57] 57.Fang N, et al. Identification of a novel melatonin-binding nuclear receptor: vitamin D receptor. J. Pineal Res. 2020;68:e12618. doi: 10.1111/jpi.12618. [DOI] [PubMed] [Google Scholar]

[CR58] 58.Genario R, Morello E, Bueno AA, Santos HO. The usefulness of melatonin in the field of obstetrics and gynecology. Pharmacol. Res. 2019;147:104337. doi: 10.1016/j.phrs.2019.104337. [DOI] [PubMed] [Google Scholar]

[CR59] 59.Corrales A, et al. Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J. Pineal Res. 2013;54:346–358. doi: 10.1111/jpi.12037. [DOI] [PubMed] [Google Scholar]

[CR60] 60.Yuge K, et al. Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders. BMC Psychiatry. 2020;20:445. doi: 10.1186/s12888-020-02847-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR61] 61.von Gall C, et al. Transcription factor dynamics and neuroendocrine signalling in the mouse pineal gland: a comparative analysis of melatonin-deficient C57BL mice and melatonin-proficient C3H mice. Eur. J. Neurosci. 2000;12:964–972. doi: 10.1046/j.1460-9568.2000.00990.x. [DOI] [PubMed] [Google Scholar]

[CR62] 62.Gómez-Corvera A, et al. Evidence of immune system melatonin production by two pineal melatonin deficient mice, C57BL/6 and Swiss strains. J. Pineal Res. 2009;47:15–221. doi: 10.1111/j.1600-079X.2009.00683.x. [DOI] [PubMed] [Google Scholar]

[CR63] 63.Acuña-Castroviejo D, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell. Mol. Life Sci. 2014;71:2997–30251. doi: 10.1007/s00018-014-1579-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR64] 64.Zhang M, Lu Y, Chen Y, Zhang Y, Xiong B. Insufficiency of melatonin in follicular fluid is a reversible cause for advanced maternal age-related aneuploidy in oocytes. Redox Biol. 2020;28:101327. doi: 10.1016/j.redox.2019.101327. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR65] 65.He, C. et al. Mitochondria synthesize melatonin to ameliorate its function and improve mice oocyte’s quality under in vitro conditions. Int. J. Mol. Sci. 17, 939 (2016). [DOI] [PMC free article] [PubMed]

[CR66] 66.Scarinci E, et al. “Hormone of darkness” and human reproductive process: direct regulatory role of melatonin in human corpus luteum. J. Endocrinol. Investig. 2019;42:1191–1197. doi: 10.1007/s40618-019-01036-3. [DOI] [PubMed] [Google Scholar]

[CR67] 67.He C, et al. Melatonin and its receptor MT1 are involved in the downstream reaction to luteinizing hormone and participate in the regulation of luteinization in different species. J. Pineal Res. 2016;61:279–290. doi: 10.1111/jpi.12345. [DOI] [PubMed] [Google Scholar]

[CR68] 68.Barilovits SJ, et al. Characterization of a mechanism to inhibit ovarian follicle activation. Fertil. Steril. 2014;101:1450–1457. doi: 10.1016/j.fertnstert.2014.01.025. [DOI] [PubMed] [Google Scholar]

[CR69] 69.Dou X, et al. Short-term rapamycin treatment increases ovarian lifespan in young and middle-aged female mice. Aging Cell. 2017;16:825–836. doi: 10.1111/acel.12617. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR70] 70.Kawamura K, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc. Natl. Acad. Sci. USA. 2013;110:17474–17479. doi: 10.1073/pnas.1312830110. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR71] 71.Li J, et al. Activation of dormant ovarian follicles to generate mature eggs. Proc. Natl. Acad. Sci. USA. 2010;107:10280–10284. doi: 10.1073/pnas.1001198107. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR72] 72.Qin X, et al. Metformin prevents murine ovarian aging. Aging. 2019;11:3785–3794. doi: 10.18632/aging.102016. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR73] 73.Tong J, et al. Melatonin levels in follicular fluid as markers for IVF outcomes and predicting ovarian reserve. Reproduction. 2017;153:443–451. doi: 10.1530/REP-16-0641. [DOI] [PubMed] [Google Scholar]

[CR74] 74.Pedersen T, Peters H. Proposal for a classification of oocytes and follicles in the mouse ovary. J. Reprod. Fertil. 1968;17:555–557. doi: 10.1530/jrf.0.0170555. [DOI] [PubMed] [Google Scholar]

[CR75] 75.Yang, C. RNA-Seq data for mice ovaries [Data set] (Zenodo, 2019).

PERMALINK

Melatonin delays ovarian aging in mice by slowing down the exhaustion of ovarian reserve

Chan Yang

Qinghua Liu

Yingjun Chen

Xiaodong Wang

Zaohong Ran

Fang Fang

Jiajun Xiong

Guoshi Liu

Xiang Li

Liguo Yang

Changjiu He

Abstract

Introduction

Results

MLT may play a regulatory role in early folliculogenesis

Fig. 1. MLT may play a regulatory role in early folliculogenesis.

MLT addition inhibited early folliculogenesis in in vitro ovary culture system

Fig. 2. MLT addition inhibited early folliculogenesis in in vitro ovary culture system.

In vivo MLT intake inhibited follicle activation through PI3K-AKT-FOXO3 pathway

Fig. 3. In vivo MLT intake inhibited follicle activation through PI3K-AKT-FOXO3 pathway.

In vivo MLT intake inhibited early follicle growth and atresia

Fig. 4. In vivo MLT intake inhibited early follicle growth and atresia.

SNAT-KO in mice accelerated the exhaustion of ovarian follicle reserve and age-related fertility decline

Fig. 5. SNAT-KO in mice accelerated the exhaustion of ovarian follicle reserve and age-related fertility decline.

Long-term intake of excessive MLT did not disturb the reproductive rhythm and growth of mice

Fig. 6. Long-term intake of excessive MLT did not disturb the reproductive rhythm, growth, and health of mice.

Discussion

Fig. 7. A proposed model to explain how MLT delays ovarian aging.

Methods

Animals

Experimental design and animal treatment

Histomorphological analysis

Ovary culture

HPLC assay on MLT

Measurements of antioxidant activity and lipid peroxidation

Superovulation, mating, and embryo count

Measurement of biochemical indexes

RNA-Seq and data analysis

Immunohistochemistry and immunofluorescence

Western blotting

PCR analysis

TUNEL staining

Statistics and reproducibility

Reporting summary

Supplementary information

Acknowledgements

Author contributions

Data availability

Competing interests

Footnotes

Supplementary information

References

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases